GPVI (E4Y9J) Rabbit mAb #45649
- WB
Supporting Data
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | 62 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
Storage
Protocol
Specificity / Sensitivity
GPVI (E4Y9J) Rabbit mAb recognizes endogenous levels of total GPVI protein.
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala258 of human GPVI protein.
Background
GPVI (GP6, Glycoprotein 6) is a collagen receptor expressed on the platelet surface that plays a key role in platelet activation, procoagulant activity, and subsequent thrombin and fibrin formation (1). On the platelet membrane, GPVI interacts with FcRγ chain to form the GPVI-FcRγ chain complex, which functions in collagen-induced platelet adhesion and activation (2,3). Upon collagen binding to GPVI, the complex is activated, resulting in ITAM domain phosphorylation of the FcRγ chain. The ITAM phosphorylation initiates the activation pathway of the Src family kinases (likely Fyn/Lyn) and Syk, as well as the subsequent activation of phospholipase C-γ2 and PI3K pathways. These activated pathways upregulate platelet adhesion and function (4). Given its important role in platelet activation, GPVI has been considered as a promising target for antithrombotic and antiplatelet treatment (5-7). Platelet activation also contributes to cancer progression (8). Platelet GPVI activated ITAM-signaling favors the extravasation of tumor cells for metastasis (9). Inhibition of platelet GPVI induces intratumor hemorrhage and increases efficacy of chemotherapy in mice, supporting the protein as a potential target for cancer treatment (10).
- Rayes, J. et al. (2019) J Clin Invest 129, 12-23.
- Nieswandt, B. and Watson, S.P. (2003) Blood 102, 449-61.
- Induruwa, I. et al. (2016) Int J Stroke 11, 618-25.
- Andrews, R.K. et al. (2014) J Blood Med 5, 59-68.
- Zahid, M. et al. (2012) J Thromb Haemost 10, 2418-27.
- Borst, O. and Gawaz, M. (2021) Pharmacol Ther 217, 107630.
- Fuentes, E. (2022) Int J Mol Sci 23, 9882. doi: 10.3390/ijms23179882.
- Schlesinger, M. (2018) J Hematol Oncol 11, 125.
- Mammadova-Bach, E. et al. (2020) Blood 135, 1146-1160.
- Volz, J. et al. (2019) Blood 133, 2696-2706.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.